

Review of: "The potential of GLP-1 RAs in treating Tobacco use dependence and Obesity"

Francesk Mulita¹

¹ General University Hospital of Patras

Potential competing interests: No potential competing interests to declare.

I was glad to review the work of the authors regarding this very interesting manuscript. The manuscript is well-written and the topic very interesting.

Despite the major advances in obesity research, there are still numerous unanswered questions regarding the mechanism of action of GLP-1 receptor agonists in obesity.

I strongly recommend acceptance for publication of the paper after minor changes.

“According to the literature, Enhanced postprandial GLP-1 release has been consistently associated with successful weight loss and successful weight loss maintenance 2–6 years after obesity surgery. In addition, GLP-1 receptor agonists used to treat diabetes type 2 have been shown to produce weight loss compared to controls. The above observations suggest that altered GLP-1 secretion may play a crucial role in weight loss after bariatric surgery.”

Add this important information to the discussion section and consider citing the related articles:

<https://pubmed.ncbi.nlm.nih.gov/36199737/>

<https://pubmed.ncbi.nlm.nih.gov/35069068/>